CLDI
Calidi Biotherapeutics Inc.
NYSE MKT: CLDI · HEALTHCARE · BIOTECHNOLOGY
$0.22
+7.53% today
Updated 2026-04-30
Market cap
$2.46M
P/E ratio
—
P/S ratio
50.83x
EPS (TTM)
$-5.95
Dividend yield
—
52W range
$0 – $13
Volume
4.3M
Calidi Biotherapeutics Inc. (CLDI) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $449000.00 | $45000.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | -90.0% | -100.0% | — | — |
| Cost of revenue | $0.00 | $94000.00 | $274000.00 | $1.26M | $1.53M | $1.65M |
| Gross profit | $0.00 | $355000.00 | $-229000.00 | $-1.26M | $-1.53M | $-1.65M |
| Gross margin | — | 79.1% | -508.9% | — | — | — |
| R&D | $3.18M | $4.67M | $7.26M | $13.01M | $8.88M | $9.74M |
| SG&A | $3.59M | $6.16M | $15.90M | $15.98M | $12.90M | $10.50M |
| Operating income | $-6.77M | $-10.48M | $-23.13M | $-28.99M | $-21.78M | $-20.24M |
| Operating margin | — | -2334.5% | -51395.6% | — | — | — |
| EBITDA | $-6.67M | $-9.45M | $-25.00M | $-24.20M | $-19.73M | $-18.59M |
| EBITDA margin | — | -2104.7% | -55551.1% | — | — | — |
| EBIT | $-6.77M | $-9.61M | $-25.26M | $-25.45M | $-21.26M | $-20.24M |
| Interest expense | $163000.00 | $614000.00 | $158000.00 | $3.75M | $933000.00 | $207000.00 |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-7.94M | $-10.93M | $-25.43M | $-29.22M | $-22.14M | $-19.91M |
| Net income growth (YoY) | — | -37.7% | -132.6% | -14.9% | +24.2% | +10.1% |
| Profit margin | — | -2435.0% | -56504.4% | — | — | — |